Home Cart Sign in  
Chemical Structure| 42464-96-0 Chemical Structure| 42464-96-0

Structure of NNMTi
CAS No.: 42464-96-0

Chemical Structure| 42464-96-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NNMTi is an effective NNMT inhibitor with potential in regulating metabolism and anti-tumor effects, used in the treatment of metabolic diseases and cancer.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NNMTi

CAS No. :42464-96-0
Formula : C10H11IN2
M.W : 286.11
SMILES Code : C[N+]1=C2C=CC=C(N)C2=CC=C1.[I-]
MDL No. :MFCD22125886
InChI Key :JPEZFBFIRRAFNR-UHFFFAOYSA-N
Pubchem ID :66522933

Safety of NNMTi

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P312-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

Description
NNMTi is a potent inhibitor of nicotinamide N-methyltransferase (NNMT), with an IC50 of 1.2 μM, selectively targeting the substrate-binding site residues of NNMT[2].

In Vitro:

Cell Line
Concentration Treated Time Description References
C2C12 myotubes 10 and 30 µM 24 hours To evaluate the effect of NNMTi on NAD+/NADH redox states in C2C12 myotubes. Results showed that NNMTi treatment increased NADH levels by 50% and decreased NAD+/NADH ratio by 40%. Biochem Pharmacol. 2019 May;163:481-492
C2C12 myoblasts 10 and 30 µM 24 hours To evaluate the effect of NNMTi on C2C12 myoblast differentiation. Results showed that 30 µM NNMTi treatment increased MHC-positive myotube nuclei by 45%, indicating enhanced myoblast differentiation. Biochem Pharmacol. 2019 May;163:481-492
RCC2 50 µM 24 hours NNMTi alone or in combination with 2-DG or BPTES significantly reduced the viability of RCC2 cells. Clin Transl Med. 2022 Jun;12(6):e883
RCC1 50 µM 24 hours NNMTi alone or in combination with 2-DG or BPTES significantly reduced the viability of RCC1 cells. Clin Transl Med. 2022 Jun;12(6):e883
A498 100 µM 24 hours NNMTi at the highest tested dose significantly inhibited the viability of A498 cells. Clin Transl Med. 2022 Jun;12(6):e883
786-O 50 µM and 100 µM 24 hours NNMTi alone or in combination with 2-DG or BPTES significantly reduced the viability of 786-O cells. Clin Transl Med. 2022 Jun;12(6):e883

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice NSCLC osimertinib-resistant xenograft model Intraperitoneal injection 10 mg/kg/day Once daily until the end of the experiment NNMTi alone or in combination with osimertinib significantly inhibited tumor growth, reducing tumor volume and weight Mol Cancer. 2025 Mar 15;24(1):79
Mice Aged mouse model Subcutaneous injection 10 mg/kg Once daily for eight weeks To evaluate the effects of NNMTi treatment and exercise interventions on age-associated muscle function. NNMTi-treated aged sedentary mice showed ~ 40% greater grip strength than sedentary controls, while aged exercised mice only showed a 20% increase relative to controls. The grip strength improvements resulting from NNMTi treatment and exercise were additive, with NNMTi-treated exercised mice developing a 60% increase in grip strength relative to sedentary controls. NNMTi treatment also promoted quantifiable improvements in IMCL content and, in combination with exercise, significantly increased gastrocnemius fiber CSA. Sci Rep. 2024 Jul 5;14(1):15554
Mice Diet-induced obese mouse model Intraperitoneal injection 4 mg/mL, 10 µL/g Daily administration for 7 weeks NNMTi treatment combined with a lean diet switch accelerated and improved body weight and fat loss, increased whole-body lean mass to body weight ratio, reduced liver and epididymal white adipose tissue (EWAT) weights, decreased liver adiposity, and improved hepatic steatosis, relative to a lean diet substitution alone. Importantly, combined lean diet and NNMTi treatment normalized body composition and liver adiposity parameters to levels observed in age-matched lean diet control mice. Sci Rep. 2021 Mar 11;11(1):5637
Mice Aged mouse muscle injury model Subcutaneous injection 5 and 10 mg/kg Twice daily for 1 week or 3 weeks To evaluate the effect of NNMTi on muscle regeneration in aged mice. Results showed that NNMTi treatment significantly increased muscle stem cell proliferation and fusion, promoted a nearly 2-fold increase in muscle fiber cross-sectional area, and improved muscle contractile function by ~70%. Biochem Pharmacol. 2019 May;163:481-492
C57BL6 mice D-galactose-induced aging mouse model Intraperitoneal injection 5 or 10 mg/kg/d Once daily for 5 weeks Evaluate the effect of NNMTi on muscle strength and muscle mass in aging mice, results showed NNMTi improved muscle strength and muscle mass Aging Cell. 2024 Sep;23(9):e14236

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.50mL

0.70mL

0.35mL

17.48mL

3.50mL

1.75mL

34.95mL

6.99mL

3.50mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories